[1] Hirschfield GM, Dyson JK, Alexander GJM, et al. The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management g uidelines. Gut, 2018,67:1568-1594. [2] Heathcote EJ. Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines. Hepatology, 2000,31:1005-1013. [3] European Association for the Study of the Liver. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. J Hepatol, 2017,67:145-172. [4] Carbone M, Sharp SJ, Flack S, et al. The UK-PBC risk scores: Derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis. Hepatology, 2016,63:930-950. [5] Lammers WJ, Hirschfield GM, Corpechot C, et al. Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy. Gastroenterology, 2015,149:1804-1812. [6] Henze L, Schwinge D, Schramm C. The Effects of Androgens on T Cells: Clues to Female Predominance in Autoimmune Liver Diseases?Front Immunol, 2020,11:1567-1570. [7] Podda M, Selmi C, Lleo A, et al. The limitations and hidden gems of the epidemiology of primary biliary cirrhosis. Autoimmun, 2013,6:81-87. [8] Tanaka A, Mori M, Matsumoto K,et al. Increase trend in the prevalence and male-to-female ratio of primary biliary cholangitis, autoimmune hepatitis, and primary sclerosing cholangitis in Japan. Hepatol Res, 2019,49:881-889. [9] Zoller B, Li X, Sundquist J, et al. Risk of pulmonary embolism in patients with autoimmune disorders: a nationwide follow-up study from Sweden.Lancet, 2012,379:244-249. [10] Carbone M, Mells GF, Pells G, et al. Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid.Gastroenterology, 2013,144:560-569. [11] Smyk DS, Rigopoulou EI, Pares A, et al. Sex differences associated with primary biliary cirrhosis. Clin Dev Immunol, 2012,60:54-61. [12] Muratori P, Granito A, Pappas G, et al. Clinical and serological profile of primary biliary cirrhosis in men. QJM, 2007,100:534-535. [13] Cheung AC, Lammers WJ, Murillo perez CF, et al. Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis. Clin Gastroenterol Hepatol, 2019,17:2076-2084. [14] Krzeski P, Zych W, Kraszewska E, et al. Is serum bilirubin concentration the only valid prognostic marker in primary biliary cirrhosis? . Hepatology, 1999,30:865-869. [15] Lammers WJ, Van buuren HR, Hirschfield GM, et al. Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. Gastroenterology,2014,147:1338-1349. [16] Murillo perez CF, Harms MH, Lindor KD, et al. Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase. Am J Gastroenterol, 2020,115:1066-1074. [17] Yang F, Yang Y, Wang Q, et al. The risk predictive values of UK-PBC and GLOBE scoring system in Chinese patients with primary biliary cholangitis: the additional effect of anti-gp210. Aliment Pharmacol Ther, 2017,45:733-743. [18] Fan X, Wang T, Shen Y, et al. Underestimated Male Prevalence of Primary Biliary Cholangitis in China: Results of a 16-yr cohort study involving 769 patients. Sci Rep, 2017,7:60-65. [19] Chen S, Duan W, Li M, et al. Prognosis of 732 ursodeoxycholic acid-treated patients with primary biliary cholangitis: A single cen ter follow-up study from China. J Gastroenterol Hepatol, 2019,34:1236-1241. [20] Lleo A, Jepsen P, Morenghi E, et al. Evolving Trends in Female to Male Incidence and Male Mortality of Primary Biliary Cholangitis. Sci Rep, 2016,6:906-918. [21] Harada K, Hirohara J, Ueno Y, et al. Incidence of and risk factors for hepatocellular carcinoma in primary biliary cirrhosis: national data from Japan. Hepatology, 2013,57:1942-1949. [22] Natarajan Y, Tansel A, Patel P, et al. Incidence of Hepatocellular Carcinoma in Primary Biliary Cholangitis: A Systematic Review and Meta-An alysis. Dig Dis Sci, 2020,8:534-543. |